• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    2/11/22 1:32:40 PM ET
    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADGI alert in real time by email

     

    Gainers

    • Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is trading at a volume of 17.7 million, which is 7371.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.2 million.
    • Vaccinex (NASDAQ:VCNX) stock moved upwards by 22.43% to $1.91. Trading volume for Vaccinex's stock is 6.4 million as of 12:30 EST. This is 588.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $75.5 million.
    • Oak Street Health (NYSE:OSH) shares increased by 15.41% to $19.32. The current volume of 2.3 million shares is 80.9% of Oak Street Health's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $4.6 billion.
    • I-MAB (NASDAQ:IMAB) shares moved upwards by 13.98% to $26.17. Trading volume for I-MAB's stock is 430.5K as of 12:30 EST. This is 67.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 billion.
    • IsoPlexis (NASDAQ:ISO) stock increased by 12.86% to $7.37. As of 12:30 EST, this security is trading at a volume of 54.3K shares, making up 26.9% of its average full-day volume over the last 100 days. The company's market cap stands at $287.0 million.
    • Viking Therapeutics (NASDAQ:VKTX) stock moved upwards by 12.33% to $4.19. As of 12:30 EST, Viking Therapeutics's stock is trading at a volume of 875.0K, which is 90.6% of its average full-day volume over the last 100 days. The company's market cap stands at $327.8 million. As per the press release, Q4 earnings came out 2 days ago.

     

    Losers

    • Adagio Therapeutics (NASDAQ:ADGI) shares fell 24.2% to $8.16 during Friday's regular session. Adagio Therapeutics's stock is trading at a volume of 7.4 million shares as of 12:30 EST. This is 87.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $907.8 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares fell 19.63% to $0.45. ENDRA Life Sciences's stock is trading at a volume of 1.0 million shares as of 12:30 EST. This is 324.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.9 million.
    • InnovAge Holding (NASDAQ:INNV) stock declined by 17.4% to $4.54. As of 12:30 EST, this security is trading at a volume of 662.1K shares, making up 81.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $614.5 million. As per the news, the Q2 earnings report came out 2 days ago.
    • Seagen (NASDAQ:SGEN) shares decreased by 14.44% to $121.0. Trading volume for this security as of 12:30 EST is 5.1 million, which is 556.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.1 billion. As per the news, the Q4 earnings report came out 2 days ago.
    • Vera Therapeutics (NASDAQ:VERA) shares fell 10.19% to $17.11. As of 12:30 EST, this security is trading at a volume of 762.9K shares, making up 1088.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $364.0 million.
    • Integrity Applications (NASDAQ:IGAP) stock declined by 10.0% to $3.15. The company's market cap stands at $48.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGI
    $DRMA
    $IGAP
    $IMAB

    CompanyDatePrice TargetRatingAnalyst
    Viking Therapeutics Inc.
    $VKTX
    10/29/2025$106.00Buy
    Canaccord Genuity
    Vera Therapeutics Inc.
    $VERA
    10/16/2025$48.00Buy
    BofA Securities
    I-MAB
    $IMAB
    10/3/2025$9.00Outperform
    Leerink Partners
    InnovAge Holding Corp.
    $INNV
    9/18/2025$5.00Underweight
    Analyst
    I-MAB
    $IMAB
    9/9/2025$7.00Buy
    BTIG Research
    Vera Therapeutics Inc.
    $VERA
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    Vera Therapeutics Inc.
    $VERA
    5/5/2025$75.00Buy
    H.C. Wainwright
    Viking Therapeutics Inc.
    $VKTX
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    SEC Filings

    View All

    SEC Form 10-K filed by Vera Therapeutics Inc.

    10-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    2/26/26 5:25:11 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    2/26/26 7:30:26 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    2/25/26 4:05:32 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

    Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad

    2/26/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

    Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a l

    2/26/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics to Participate at Upcoming Investor Conferences

    BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: TD Cowen 46th Annual Health Care ConferenceFormat: Fireside chat and 1x1 investor meetings Webcast: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/Etdv38YcyjD9fFRQNSrAUoDate: Tuesday, March 3, 2026Time: 11:10am ET Location: Boston, MA Barclays 28th Annual Global He

    2/24/26 8:00:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    6/25/25 8:07:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zoretic Richard C bought $173,307 worth of shares (42,715 units at $4.06), increasing direct ownership by 166% to 68,494 units (SEC Form 4)

    4 - InnovAge Holding Corp. (0001834376) (Issuer)

    5/30/25 5:08:25 PM ET
    $INNV
    Medical/Nursing Services
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Brenner Robert sold $90,307 worth of shares (2,151 units at $41.98), decreasing direct ownership by 4% to 50,947 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 8:01:07 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R sold $130,864 worth of shares (3,117 units at $41.98), decreasing direct ownership by 5% to 64,722 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 8:00:18 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Grant Sean sold $207,778 worth of shares (4,949 units at $41.98), decreasing direct ownership by 4% to 114,181 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 7:59:26 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Viking Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $106.00

    10/29/25 7:54:28 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Vera Therapeutics with a new price target

    BofA Securities initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $48.00

    10/16/25 8:29:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on I-Mab with a new price target

    Leerink Partners initiated coverage of I-Mab with a rating of Outperform and set a new price target of $9.00

    10/3/25 8:40:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut

    11/26/25 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    11/18/24 4:15:28 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Financials

    Live finance-specific insights

    View All

    Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended

    2/11/26 4:16:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

    Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time  SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

    2/4/26 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025

    DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. ("InnovAge" or the "Company") (NASDAQ:INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal second quarter ended December 31, 2025. "InnovAge delivered strong operating and financial results this quarter, reflecting continued progress in building a scalable, high-quality PACE platform," said Patrick Blair, CEO. "Our performance is rooted in disciplined execution and a care model that prioritizes clinical outcomes, participant experience, and respon

    2/3/26 4:05:00 PM ET
    $INNV
    Medical/Nursing Services
    Health Care